Risk of bacteraemia and mortality in patients with haematological malignancies  by Nørgaard, M. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01298.x
Risk of bacteraemia and mortality in patients with haematological
malignancies
M. Nørgaard1,2, H. Larsson1, G. Pedersen3,4, H. C. Schønheyder5 and H. T Sørensen1
1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Department of
Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN,
USA, 3Department of Haematology, 4Department of Infectious Diseases and 5Department of Clinical
Microbiology, Aalborg Hospital–Aarhus University Hospital, Aalborg, Denmark
ABSTRACT
This study examined the association between type of haematological malignancy, risk of bacteraemia
and risk of mortality, with emphasis on the impact of bacteraemia type on mortality. A population-
based cohort design was used, and all patients aged ‡ 15 years with an incident haematological
malignancy who were living in North Jutland County, Denmark, during 1992–2002 were included in the
study. Among 1666 patients with an incident haematological malignancy, 358 (21%) suffered an episode
of bacteraemia during a median follow-up period of 1.1 years (quartile 0.2–3.4) from the date of cancer
diagnosis (overall incidence rate of 96 ⁄ 1000 person-years). In comparison to Hodgkin’s disease, adjusted
incidence rate ratios (IRRs) were 23.3 (95% CI, 10.0–54.5) for acute myeloid leukaemia, 3.8 (95% CI, 1.5–
9.3) for multiple myeloma, and 2.2 (95% CI, 0.9–5.1) for non-Hodgkin’s lymphoma or chronic lymphatic
leukaemia. Overall cumulative 30-day mortality was 32% (95% CI, 27–37), and 90-day mortality was
50% (95% CI, 44–55). In comparison with acute myeloid leukaemia, adjusted mortality rate ratios
(MRRs) were close to 1.0 for other haematological malignancies. In comparison to bacteraemia caused by
Gram-positive bacteria, adjusted MRRs were 1.0 (95% CI, 0.6–1.5) for Gram-negative bacteraemia, and
1.9 (95% CI, 1.1–3.3) for polymicrobial bacteraemia or fungaemia. Thus, the risk of bacteraemia varied
greatly according to the type of malignancy, while mortality rates were similar for these diseases,
although dependent on the type of bacteraemia. Polymicrobial bacteraemia or fungaemia was associated
with higher mortality.
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INTRODUCTION
Haematological malignancies are a heterogeneous
group of cancers with differing survival rates, but
long-term survival has, in general, improved
during the last few decades [1–5]. Improved
treatment, including use of high-dose therapy
with either autologous or allogeneic stem-cell
rescue, combined with advances in supportive
care [1], may be responsible for this positive
trend. It has long been recognised that infections
are among the most serious problems faced by
patients with haematological malignancies [6],
with the risk of infection being related to the
degree and duration of neutropenia [7]. The
haematological malignancy itself may disrupt
the immune response to infection. In addition,
most cytostatic treatment is highly immunosup-
pressive and predisposes patients to infections.
Bacteraemia can be detected in 30–40% of febrile
neutropenic patients [8].
Several studies in clinical settings have exam-
ined mortality among patients with haematologi-
cal malignancies who contract bacteraemia [9–16].
Most studies have focused on neutropenic pa-
tients [9,10,14–16] identified at referral centres,
making the general applicability of the findings
uncertain, and most were performed during the
1980s, with only one study including data from
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the late 1990s [11]. To date, little is known
regarding the incidence of bacteraemia among
patients with haematological malignancies in
a population-based setting. Accordingly, the
present cohort study investigated the risk of bac-
teraemia and the associated mortality among
patients with haematological malignancies, using
population-based registries in North Jutland
County, Denmark. The specific aims were to
estimate the incidence rate of bacteraemia, to
examine variations in mortality rates resulting
from bacteraemia in patients with different haem-
atological malignancies, and to examine whether
the type of bacteraemia had an impact on mortality
rates. This information is of utmost importance to
clinicians seeking to identify high-risk patients
and target them for new treatment modalities.
MATERIALS AND METHODS
Study population
The study was conducted in North Jutland County, Denmark
(population c. 500 000) during 1992–2002. Residents receive
free, tax-supported healthcare, and haematology patients with
bacteraemia were treated in one of seven public hospitals. One
of these, Aalborg Hospital, served as both a district and a
referral hospital. The Department of Clinical Microbiology at
Aalborg Hospital performed bacteriological analyses on
samples collected from patients throughout the county. As
stem-cell and bone marrow transplantation were not available
in North Jutland County, patients requiring these treatments
were transferred outside the county to a nationwide centre.
Identification of patients with a haematological malignancy
The County Hospital Discharge Registry (HDR) was used to
identify patients, aged ‡ 15 years, with a first diagnosis of a
haematological malignancy during the period 1 January 1992
to 30 November 2002. The HDR [17], established in 1977,
contains data on > 99% of all hospital discharges within the
county, including civil registration numbers, dates of admis-
sion and discharge, surgical procedure(s) performed, and up
to 20 discharge diagnoses, classified according to the Interna-
tional Classification of Diseases (ICD). The 8th revision was
used until the end of 1993, and the 10th revision was used
thereafter. Haematological malignancies were classified as
follows: acute myeloid leukaemia (ICD-8 code 205.09 and ICD-
10 code C92.0), Hodgkin’s disease (ICD-8 code 201.99 and
ICD-10 code C81.0-9), non-Hodgkin’s lymphoma or chronic
lymphocytic leukaemia (ICD-8 codes 200.09-19, 202.09-29,
204.19, 275.59, 275.90; and ICD-10 codes C82.0-85.9, C88.0-9,
C91.1, C96.0-9) and multiple myeloma (ICD-8 code 203.99 and
ICD-10 code C90.0-2). Remaining haematological malignan-
cies, including chronic myeloid leukaemia, were classified as
‘other’.
Since coding errors occur, hospital discharge diagnoses are
not always completely accurate. For this reason, patients were
also required to be registered in the Danish Cancer Registry
(DCR) in order to be included in the study. The DCR is a
population-based nationwide registry containing data on
incident cancer cases in Denmark since 1943 [18]. Its records
include civil registration numbers, the method used to verify
the cancer diagnosis, clinical stage, and residence at time of
diagnosis. Annual linkage to the national HDR and the
National Death Certificate Files ensures that cases not reported
to the DCR are included subsequently. The DCR has been
shown to be > 95% complete [18].
Identification of episodes of bacteraemia
Since 1981, all episodes of bacteraemia in North Jutland
County have been recorded in the County Bacteraemia
Registry [19], maintained by the Department of Clinical
Microbiology, Aalborg Hospital. Departmental physicians
report each episode to the registry. Information has been
recorded prospectively since 1992. The registry contains data
on bacterial isolates and susceptibility patterns, as well as the
following patient information: age, gender, admission date,
presumed focus of infection, and civil registration number.
This registry was used to identify all patients with a first
episode of bacteraemia subsequent to the diagnosis date of
their haematological malignancy, during the period 1 January
1992 to 31 December 2002.
Bacteraemia was defined as bacterial or fungal growth in
blood cultures. The aetiological significance of the isolated
pathogen was based on clinical and microbiological assess-
ment. Coagulase-negative staphylococci, Bacillus spp., Coryne-
bacterium spp. and Propionibacterium acnes were regarded as
contaminants unless isolated from two or more separate blood
culture sets.
Three different systems for blood culture were used during
the study period. In 1992, a 12-tube system was employed, in
which blood samples were inoculated on arrival at the labor-
atory into sets of bacteriological media (four tubes of nutrient
broth, four tubes of semi-solid nutrient agar, and four tubes of
semi-solid thioglycollate agar). During 1992–1995, the Colorbact
system (Statens Serum Institut, Copenhagen, Denmark) was
used, in which blood was sampled directly into a set of three
broth culture bottles, two aerobic and one anaerobic [20]. From
1996 onwards, the BacT ⁄Alert system (bioMe´rieux, Marcy-
l’Etoile, France) was used, which also required that blood be
sampled directly into a set of three broth culture bottles, two
aerobic and one anaerobic. The nominal volume per blood
culture for the three systems was 16–18 mL, 20–22 mL and 28–
32 mL, respectively, for adult patients. Bacteraemia was classi-
fied as Gram-positive bacteraemia, Gram-negative bacteraemia,
polymicrobial bacteraemia or fungaemia.
Other clinical data
On first notification of a positive blood culture, the empirical
antibiotic therapy given to the patient was recorded in the
Bacteraemia Registry. Therapy was considered appropriate if
given intravenously (with the exceptions of fluoroquinolones
and metronidazole), and if the blood isolate was susceptible
to one or more of the antimicrobial agents administered.
Empirical treatment was considered inappropriate if the
isolates were resistant, or if doses or the form of adminis-
tration were insufficient [21,22]. In some cases, patients had
already died, or treatment had been withdrawn because the
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patients were terminally ill. Antibiotic, antiviral or antifungal
prophylaxis was not used for neutropenic patients during
the study period.
Patients were considered neutropenic if their neutrophil
count on the date of the positive blood culture was
< 0.5 · 109 ⁄L or, for cases in which no neutrophil count was
recorded, if the total leukocyte count was < 0.5 · 109 ⁄L. If a
white blood cell count was lacking on the date of the positive
blood culture, the latest available blood count within the week
preceding the positive blood culture was used. For the 1992–
1997 period, data were retrieved from medical records; from
1997 onwards, computerised laboratory data were available.
Co-morbidity was classified according to the Charlson
co-morbidity index [23]. This index is considered to be a valid
method for measuring co-morbidity for clinical research
purposes [24]. A weight is assigned to define categories of
co-morbid diseases, and the index is the sum of these weights.
Malignant diseases are categorised as tumour, lymphoma,
leukaemia or metastatic cancer. The Charlson index was
calculated on the basis of ICD codes for all previous discharge
diagnoses in the discharge registry, except for leukaemia and
lymphoma, which were the index diseases.
Three levels of co-morbidity were defined: 0 (low), corres-
ponding to patients with no recorded underlying diseases
included in the Charlson index; 1–2 (medium); and > 2 (high)
[25].
Mortality data
A ten-digit civil registration number is assigned to all Danish
citizens shortly after birth by the Central Office of Civil
Registration, and this allows accurate linkage between data-
bases. The Civil Registration system, updated daily, also
contains information for Danish citizens concerning vital
status (dead or alive), date of death, and residence. In order
to be included in the present study, patients were required to
be resident in North Jutland County at the time of haemato-
logical diagnosis. The vital status of all study patients was
recorded on 1 January 2003.
Statistical analysis
The incidence rate of bacteraemia and the summarised risk
over time were calculated by Kaplan–Meier analysis. The
admission date for the initial haematological malignancy was
used as time of entry. Patients were followed until their first
episode of bacteraemia, death, or until 31 December 2002,
whichever came first. Cox regression analysis was used to
estimate incidence rate ratios (IRRs) by type of haematological
malignancy after follow-up for 1 year. Analyses were adjusted
by age, gender and co-morbidity. Kaplan–Meier survival
curves were constructed for the main study variables, based
on the date of the patient’s first positive blood culture; the risk
of death after 30 and 90 days was also estimated. Main study
variables were age group, gender, malignancy type, co-
morbidity and type of bacteraemia. Cox regression analysis
was used to estimate the mortality rate ratio (MRR) and 95%
CI for the different types of malignancy, with acute myeloid
leukaemia as the reference, adjusting for age group (< 40 years
as the reference), gender (male as the reference), type of
bacteraemia (Gram-positive as the reference), co-morbidity as
assessed by the Charlson index (low as the reference),
neutropenia (neutrophil count ‡ 0.5 · 109 ⁄L as the reference)
and empirical antibiotic treatment (appropriate treatment as
the reference). Assumptions were assessed graphically and
found to be appropriate. The initial statistical model included
the variables ‘time between diagnosis of the haematological
malignancy and first episode of bacteraemia’ and ‘calendar
time’ as possible confounders. However, as these variables did
not affect the values of the other variables in the adjusted
analysis, they were excluded from the final model. Statistical
analyses were performed using Stata Statistical Software v. 8.0
(Stata Corp., College Station, TX, USA).
RESULTS
Incidence and risk of bacteraemia
In total, 1666 patients with an incident haemato-
logical malignancy were identified, including
926 (56%) men and 740 (44%) women. Acute
myeloid leukaemia was diagnosed in 169 (10%)
patients, Hodgkin’s disease in 111 (7%), multiple
myeloma in 245 (15%), and non-Hodgkin’s lym-
phoma or chronic lymphatic leukaemia in 943
(57%). The remaining 198 patients, including 51
with chronic myeloid leukaemia, were catego-
rised as ‘other’. Of these 1666 patients, 358 (21%)
experienced an initial episode of bacteraemia
during a median follow-up period of 1.1 years
(quartile 0.2–3.4) starting from the date of the
cancer diagnosis. The overall incidence rate was
96 cases ⁄ 1000 person-years. For 246 (15%) pa-
tients, the initial episode of bacteraemia occurred
within the first year following diagnosis. Fig. 1
shows the cumulative incidence by type of haem-
atological malignancy during this period, and
shows a large variation in the risk of bacteraemia
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Fig. 1. Cumulative incidence of bacteraemia among 1666
patients with different types of haematological malignancy
in the year following diagnosis. CLL, chronic lymphocytic
leukaemia.
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for different types of malignancy. In relation to
Hodgkin’s disease, bacteraemia IRRs, adjusted for
age, gender and co-morbidity, were 23.3 (95% CI,
10.0–54.5) for acute myeloid leukaemia, 3.8 (95%
CI, 1.5–9.3) for multiple myeloma, 2.2 (95% CI,
0.9–5.1) for non-Hodgkin’s lymphoma or chronic
lymphatic leukaemia, and 8.3 (95% CI, 3.5–19.6)
for other haematological malignancies.
Mortality
The crude 7-day mortality rate for patients with
bacteraemia was 17% (95% CI, 13–21), the 30-day
mortality rate was 32% (95% CI, 27–37), and the
90-day mortality rate was 50% (95% CI, 44–55)
(Fig. 2). Table 1 shows the clinical and demogra-
phic characteristics of the study patients, inclu-
ding crude 30-day mortality rates.
Table 2 shows crude and adjusted MRRs after
follow-up for 30 and 90 days. In comparison to
acute myeloid leukaemia, crude MRRs after
follow-up for 30 days were 1.2 (95% CI, 0.4–3.5)
for Hodgkin’s disease, 1.1 (95% CI, 0.6–2.1) for
multiple myeloma, and 0.9 (95% CI, 0.5–1.5)
for non-Hodgkin’s lymphoma or chronic lymph-
ocytic leukaemia. Adjustment by age group,
co-morbidity, gender, type of bacteraemia, neu-
tropenia and appropriateness of empirical antibi-
otic therapy did not change the 30-day MRRs
substantially. Adjusted MRRs were indistinguish-
able from 1.0 for each type of malignancy.
Similar mortality estimates were found after
follow-up for 90 days. In comparison to acute
myeloid leukaemia, adjusted MRRs were 1.5
(95% CI, 0.6–3.7) for Hodgkin’s disease, 1.0
(95% CI, 0.6–1.8) for multiple myeloma, and 0.9
(95% CI, 0.6–1.3) for non-Hodgkin’s lymphoma or
chronic lymphocytic leukaemia.
Type of microorganism and mortality rates
Gram-positive organisms caused 35% of the
episodes of bacteraemia, and Gram-negative
organisms caused 50%. In 14% of cases, the first
episode of bacteraemia was polymicrobial.
Escherichia coli was the most common cause of
bacteraemia (25% of all first episodes of bacter-
aemia) (Table 1), while yeast and anaerobes were
the least common (1% of all first episodes,
respectively). Staphylococcus aureus was the most
common Gram-positive organism, isolated in
13% of all first episodes. Among the 50 episodes
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Fig. 2. Kaplan–Meier curve for 358 patients with bacter-
aemia and an underlying haematological malignancy.
Grey lines indicate 95% CIs.
Table 1. Clinical and demographic characteristics of 358
patients with a newly diagnosed haematological malig-
nancy who experienced a first episode of bacteraemia
during the study period
Number (%)
30-day mortality
% (95% CI)
Total 358 32 (27–37)
Type of haematological malignancy
Acute myeloid leukaemia 81 (23) 30 (21–41)
Hodgkin’s disease 13 (4) 31 (13–63)
Multiple myeloma 52 (15) 37 (25–51)
Non-Hodgkin’s lymphoma or
chronic lymphocytic leukaemia
157 (44) 27 (21–35)
Other 55 (15) 44 (32–58)
Type of bacteraemia
Staphylococcus aureus 45 (13) 31 (20–47)
Coagulase-negative staphylococci 15 (4) 33 (15–62)
b-Haemolytic streptococci 8 (2) 38 (14–77)
Streptococcus pneumoniae 34 (10) 21 (10–38)
Other Gram-positive organisms 20 (6) 30 (15–55)
Escherichia coli 88 (25) 29 (20–39)
Other Enterobacteriaceae 36 (10) 31 (18–48)
Pseudomonas aeruginosa 33 (9) 27 (15–46)
Other Gram-negative microorganisms 19 (5) 42 (24–67)
Anaerobes 5 (1) 20 (3–80)
Yeasts 5 (1) 60 (25–95)
Polymicrobial 50 (14) 44 (32–59)
Gender
Male 197 (55) 36 (29–43)
Female 161 (45) 28 (21–35)
Age (years)
15–39 45 (13) 9 (3–22)
40–59 116 (32) 28 (20–37)
60–79 162 (45) 37 (30–45)
‡ 80 35 (10) 51 (36–69)
Neutropenia
Neutrophil count ‡ 0.5 · 109 ⁄L 229 (64) 29 (24–36)
Neutrophil count < 0.5 · 109 ⁄L 110 (31) 38 (30–48)
Missing 19 (5) 26 (12–52)
Co-morbidity index
Low (0) 214 (60) 30 (24–37)
Medium (1–2) 105 (29) 31 (23–40)
High (> 2) 39 (11) 46 (32–63)
Empirical antibiotic treatment
Appropriate 225 (64) 25 (20–32)
Inappropriate 106 (30) 35 (27–45)
Treatment withdrawna 19 (5) 100
aThe patients died or were terminally ill.
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of polymicrobial bacteraemia, E. coli was isolated
in 30 (60%) cases and S. aureus was isolated in
seven (14%) cases. The lowest crude 30-day
mortality rates were found among patients infec-
ted with Streptococcus pneumoniae (21%) and
anaerobes (20%), and the highest rates were
among patients with polymicrobial bacteraemia
(44%) and fungaemia (60%) (Table 1).
Compared to patients with Gram-positive bac-
teraemia, patients with polymicrobial bacteraemia
or fungaemia had higher mortality rates after
follow-up for 30 days (Table 2). The crude MRR
for polymicrobial bacteraemia or fungaemia was
1.9 (95% CI, 1.1–3.2), and the adjusted MRR was
1.9 (95% CI, 1.1–3.3). In contrast, patients with
Gram-negative bacteraemia did not have a sub-
stantially increased mortality rate compared to
patients with Gram-positive bacteraemia; the
crude MRR was 1.1 (95% CI, 0.7–1.7), and the
adjusted MRR was 1.0 (95% CI, 0.6–1.5). After
follow-up for 90 days, the adjusted MRR for
polymicrobial bacteraemia or fungaemia was 1.4
(95% CI, 0.9–2.3). For Gram-negative bacteraemi-
as vs. Gram-positive bacteraemias, the adjusted
MRR was 0.9 (95% CI, 0.7–1.3). The sample size
was too small to permit stratified analysis of the
impact of the microbiological agent by type of
haematological malignancy.
Other factors
Neutropenia, present at the onset of bacteraemia
in 31% of patients, was associated with a higher
mortality rate (adjusted 30-day MRR = 1.9; 95%
CI, 1.2–3.0). The sample size did not allow
stratified analysis according to the presence or
absence of neutropenia. Inappropriate empirical
antibiotic treatment was recorded in the Bacter-
aemia Registry [19] for 30% of patients. This was
also associated with a modest, non-significant,
increase in mortality (adjusted 30-day MRR = 1.4;
95% CI, 0.9–2.1).
DISCUSSION
In this population-based study of 1666 patients
hospitalised with a newly diagnosed haematolog-
ical malignancy, the risk of bacteraemia during
the following year was found to vary substan-
tially according to the type of malignancy. While
Table 2. Type of haematological malignancy, bacteraemia and other factors associated with 30- and 90-day mortality
resulting from bacteraemia among patients with haematological malignancies
Risk-factor N
30-day mortality 90-day mortality
Crude MRR
(95% CI)
Adjusted MRR
(95% CI)
Crude MRR
(95% CI)
Adjusted MRRa
(95% CI)
Type of haematological malignancy
Acute myeloid leukaemia 81 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Hodgkin’s disease 13 1.2 (0.4–3.5) 1.1 (0.3–3.8) 1.4 (0.6–3.2) 1.5 (0.6–3.7)
Multiple myeloma 52 1.3 (0.7–2.5) 1.2 (0.6–2.3) 1.2 (0.7–2.0) 1.0 (0.6–1.8)
Non-Hodgkin’s lymphoma or
chronic lymphocytic leukaemia
157 0.9 (0.6–1.6) 0.7 (0.4–1.2) 1.1 (0.8–1.7) 0.9 (0.6–1.3)
Other 15 1.6 (0.9–2.9) 1.1 (0.6–2.1) 1.4 (0.8–2.2) 1.0 (0.6–1.7)
Type of bacteraemia
Gram-positive 125 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Gram-negative 178 1.1 (0.7–1.7) 1.0 (0.6–1.5) 1.0 (0.7–1.4) 0.9 (0.7–1.3)
Polymicrobial or fungaemia 55 1.9 (1.1–3.2) 1.9 (1.1–3.3) 1.4 (0.9–2.1) 1.4 (0.9–2.3)
Gender
Male 197 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Female 161 0.8 (0.5–1.1) 0.8 (0.6–1.2) 0.8 (0.6–1.0) 0.8 (0.6–1.1)
Age (years)
15–39 45 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
40–59 116 3.3 (1.2–9.4) 5.6 (1.7–18.8) 1.8 (0.4–3.3) 2.4 (1.2–4.7)
60–79 162 4.9 (1.8–13.5) 7.7 (2.3–25.7) 2.7 (1.5–5.0) 3.4 (1.7–6.6)
‡ 80 35 7.1 (2.4–21.1) 12.1 (3.4–43.2) 3.7 (1.9–7.4) 4.7 (2.1–10.2)
Neutropenia
Neutrophil count ‡ 0.5 · 109 ⁄L 229 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Neutrophil count < 0.5 · 109 ⁄L 110 1.4 (1.0–2.1) 1.9 (1.2–3.0) 1.1 (0.8–1.5) 1.1 (0.8–1.6)
Co-morbidity index
Low (0) 214 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Medium (1–2) 105 1.0 (0.7–1.6) 1.1 (0.7–1.7) 1.2 (0.8–1.7) 1.1 (0.8–1.6)
High (> 2) 39 1.7 (1.0–2.8) 1.9 (1.1–3.6) 1.8 (1.1–2.7) 1.8 (1.1–2.9)
Empirical antibiotic treatmenta
Appropriate 225 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
Inappropriate 106 1.4 (1.0–2.2) 1.4 (0.9–2.1) 1.4 (1.0–2.0) 1.4 (1.0–2.0)
aExcluding 19 patients whose treatment had been withdrawn.
MRR, mortality rate ratio.
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the type of malignancy did not affect mortality,
the type of bacteraemia had a significant impact.
Polymicrobial bacteraemia or fungaemia were
associated with higher mortality, while the mor-
tality rate did not differ significantly between
patients with Gram-negative and Gram-positive
bacteraemia.
To the best of our knowledge, this is the first
study using a population-based bacteraemia
registry to examine the risk of bacteraemia in
patients with haematological malignancies. It is
also the first study to document 90-day mortality
rates in patients with haematological
malignancies and bacteraemia. The finding of a
30-day mortality rate of c. 30% for these patients
accords with the results of several studies con-
ducted in tertiary-care facilities [10,12,13]. One
study reported a 30-day mortality rate of only
16% in 1402 episodes of bacteraemia in 927
patients with haematological disorders [11], but
did not adjust for age or other potential con-
founding factors, and was not restricted to the
first episode of bacteraemia. The impact of the
underlying type of malignancy on mortality rates
has been addressed in two studies that focused
solely on neutropenic patients [9,10], which found
similar mortality rates among patients with dif-
ferent types of haematological malignancy.
The present study showed that the presence of
polymicrobial bacteraemia or fungaemia had a
significant effect on 30-day mortality rates, con-
sistent with the results of two other studies
[12,15]. However, the finding that mortality rates
did not differ substantially between patients with
Gram-positive and Gram-negative bacteraemia
contradicts the results of previous studies con-
ducted by the International Antimicrobial Ther-
apy Cooperative Group of the European
Organization for Research and Treatment of
Cancer (IATCG-EORTC) [26–28]. In the first four
EORTC trials, combined mortality (defined as
death from infection within 9 days of start of
therapy) was 4% for Gram-positive and 12% for
Gram-negative bacteraemias [28]. The EORTC
trials encompassed 1074 granulocytopenic
patients from 24 different institutions, random-
ised to different antibiotic treatment regimens.
These trials included children, and the patients
may have been specially selected, thereby provi-
ding a possible explanation for a lower mortality
rate than was observed in the present population-
based study. Also, the EORTC trials were not
restricted to the first episode of bacteraemia,
which may influence mortality rates differently
among patients with Gram-positive and Gram-
negative bacteraemias.
The validity of the findings depends on data
quality, completeness of follow-up, and ability
to control for confounding factors. The main
strengths of the present study were its large
size, its population-based design with complete
follow-up (permitted by the uniform organisa-
tion of the healthcare system throughout Den-
mark), and the high quality and completeness of
the cancer and bacteraemia data [29]. Overall
mortality was used as the outcome variable. As
this is determined by factors related to the acute
infection, underlying disorders, and supportive
and antibiotic treatment, it is difficult to define
the contributions of the septic process and
underlying disorders to mortality [30]. However,
most deaths within the first month of a diag-
nosis of bacteraemia are likely to be related to
the infection. This assumption is supported by
the fact that mortality within this short time-
frame depends highly on the appropriateness of
early antibiotic therapy [31,32]. In the present
study, c. 20% of patients died 30–90 days after
their first positive blood culture. It is probable
that these deaths were related to the original
infection or to an interaction between infection
and the underlying malignancy. Therefore, the
90-day follow-up period was considered to be a
strength of the study, because it allowed the
suggestion that bacteraemia following diagnosis
of a haematological malignancy is a warning
sign for curtailed long-term survival. The Charl-
son Index [23] was used to control for con-
founding by co-morbidity. However, while this
index is used widely, it cannot control for
confounding as completely as clinical data [32].
In conclusion, bacteraemia was frequent in
patients with haematological malignancies and
was associated with high mortality rates. The
cumulative incidence of bacteraemia, but not the
mortality associated with bacteraemia, varied by
type of malignancy. The present study suggests
that prophylactic strategies for bacteraemia
should be tailored to the type of haematological
malignancy, while strategies for treating bacter-
aemia should be standardised. Special attention
must be given to polymicrobial bacteraemia and
fungaemia, both of which were associated with
higher 30-day mortality rates.
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